6,216 results match your criteria Narcolepsy


Clinical characteristics of a large cohort of patients with narcolepsy candidate for pitolisant: a cross-sectional study from the Italian PASS Wakix® Cohort.

Neurol Sci 2022 Jun 25. Epub 2022 Jun 25.

Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze, Università di Modena e Reggio-Emilia, Modena, Italy.

Introduction: Narcolepsy is a chronic and rare hypersomnia of central origin characterized by excessive daytime sleepiness and a complex array of symptoms as well as by several medical comorbidities. With growing pharmacological options, polytherapy may increase the possibility of a patient-centered management of narcolepsy symptoms. The aims of our study are to describe a large cohort of Italian patients with narcolepsy who were candidates for pitolisant treatment and to compare patients' subgroups based on current drug prescription (drug-naïve patients in whom pitolisant was the first-choice treatment, switching to pitolisant from other monotherapy treatments, and adding on in polytherapy). Read More

View Article and Full-Text PDF

Pfizer/BioNTech SARS-CoV-2 vaccine as a potential trigger for the development of narcolepsy: a case report.

J Clin Sleep Med 2022 Jun 23. Epub 2022 Jun 23.

Loewenstein Rehabilitation Medical Center, Raanana, Israel.

Narcolepsy is a rare condition in Israel. Currently, the incidence of narcolepsy following SARS-CoV-2 vaccination in Israel is unknown. We are reporting a case report of a 51-year-old female of Ashkenazi Jewish descent who was evaluated for complaints of excessive daytime sleepiness and relative functional decline that immediately followed receipt of the Pfizer/BioNTech SARS-CoV-2 vaccination. Read More

View Article and Full-Text PDF

IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis.

Eur Rev Med Pharmacol Sci 2022 Jun;26(11):4074-4081

Department of Computer Science, College of Computers and Information Technology, Taif University, Taif, Saudi Arabia.

Objective: Atopic dermatitis displays a relevant sleep burden sustained by clinical (i.e., itch), psychological (i. Read More

View Article and Full-Text PDF

Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study.

BMJ 2021 06 14;373:n1435. Epub 2021 Jun 14.

Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK

Objective: To quantify the background incidence rates of 15 prespecified adverse events of special interest (AESIs) associated with covid-19 vaccines.

Design: Multinational network cohort study.

Setting: Electronic health records and health claims data from eight countries: Australia, France, Germany, Japan, the Netherlands, Spain, the United Kingdom, and the United States, mapped to a common data model. Read More

View Article and Full-Text PDF

Revisiting Preclinical Observations of Several Histamine H3 Receptor Antagonists/Inverse Agonists in Cognitive Impairment, Anxiety, Depression, and Sleep-Wake Cycle Disorder.

Front Pharmacol 2022 1;13:861094. Epub 2022 Jun 1.

Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.

A relationship appears to exist between dysfunction of brain histamine (HA) and various neuropsychiatric brain disorders. The possible involvement of brain HA in neuropathology has gained attention recently, and its role in many (patho)physiological brain functions including memory, cognition, and sleep-wake cycle paved the way for further research on the etiology of several brain disorders. Histamine H3 receptor (H3R) evidenced in the brains of rodents and humans remains of special interest, given its unique position as a pre- and postsynaptic receptor, controlling the synthesis and release of HA as well as different other neurotransmitters in different brain regions, respectively. Read More

View Article and Full-Text PDF

A comparison of mood, quality of life and executive function among narcolepsy type 1 patients with or without ADHD symptoms in China.

Sleep Med 2022 May 31;97:47-54. Epub 2022 May 31.

Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, China. Electronic address:

Objective: To investigate the prevalence of core attention-deficit/hyperactivity disorder (ADHD) symptoms in Chinese narcolepsy type 1 (NT1) patients and to explore mood, quality of life, and executive function in narcolepsy patients with or without ADHD and the response to Methylphenidate Hydrochloride Extended-release tablets (ER-MPH) treatment.

Method: A total of 267 pediatric NT1 patients (194 males and 73 females, 5-17 years old) were evaluated for ADHD symptoms by a psychiatrist using the DSM-IV diagnostic criteria of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI Kid) from February 2011 to July 2013 at Peking University People's Hospital. All patients underwent Stanford Sleep Inventory (SSI) evaluation and polysomnography followed by multiple sleep latency tests (MSLT) before ER-MPH treatment. Read More

View Article and Full-Text PDF

Solriamfetol for the Use of Narcolepsy: A Systematic Review.

Cureus 2022 May 12;14(5):e24937. Epub 2022 May 12.

Neurology, Alluri Sitaramaraju Academy of Medical Sciences, Eluru, IND.

Narcolepsy is a chronic and disabling neurological disorder characterized by excessive daytime sleepiness (EDS) and cataplexy. Historically, some medications have demonstrated efficacy in managing EDS and cataplexy symptoms. However, some patients cannot tolerate them, become refractory, or may use concomitant medications that preclude the use due to drug-drug interaction. Read More

View Article and Full-Text PDF

Hyperhidrosis in sleep disorders - A narrative review of mechanisms and clinical significance.

J Sleep Res 2022 Jun 15:e13660. Epub 2022 Jun 15.

Laboratorio de Neurobiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.

Hyperhidrosis is characterized by excessive sweating beyond thermoregulatory needs that affects patients' quality of life. It results from an excessive stimulation of eccrine sweat glands in the skin by the sympathetic nervous system. Hyperhidrosis may be primary or secondary to an underlying cause. Read More

View Article and Full-Text PDF

The orexin story, sleep and sleep disturbances.

J Sleep Res 2022 Jun 13:e13665. Epub 2022 Jun 13.

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.

The orexins, also known as hypocretins, are two neuropeptides (orexin A and B or hypocretin 1 and 2) produced by a few thousand neurons located in the lateral hypothalamus that were independently discovered by two research groups in 1998. Those two peptides bind two receptors (orexin/hypocretin receptor 1 and receptor 2) that are widely distributed in the brain and involved in the central physiological regulation of sleep and wakefulness, orexin receptor 2 having the major role in the maintenance of arousal. They are also implicated in a multiplicity of other functions, such as reward seeking, energy balance, autonomic regulation and emotional behaviours. Read More

View Article and Full-Text PDF

Adjustment to lockdown in children and adolescents with narcolepsy in France.

J Clin Sleep Med 2022 Jun 14. Epub 2022 Jun 14.

Pediatric Sleep Center, Hospital Robert-Debré, Paris, 48 Boulevard Serurier Paris, France.

Study Objectives: The goal of the current study was to explore the effect of a 2-month quarantine on children and adolescents with narcolepsy and to describe the changes in their sleep, mood, and metabolism during this period.

Methods: The study involved 77 patients aged 7 to 23 years with a diagnosis of narcolepsy. Participants had to answer multiple-choice questions to characterize the changes and modifications in their own habits and state of health. Read More

View Article and Full-Text PDF

Increased Incidence of Pediatric Narcolepsy Following the 2009 H1N1 Pandemic: A Report from the Pediatric Working Group of the Sleep Research Network.

Sleep 2022 Jun 13. Epub 2022 Jun 13.

Division of Biostatistics and Epidemiology; Cincinnati Children's Hospital Medical Center, Ohio, USA.

This study was aimed to evaluate yearly incidence of pediatric narcolepsy prior to and following the 2009 H1N1 pandemic and to evaluate seasonal patterns of narcolepsy onset and associations with H1N1 influenza infection in the United States. This was a multi-center retrospective study with prospective follow-up. Participants were recruited from members of the Pediatric Working Group of the Sleep Research Network including 22 sites across the United States. Read More

View Article and Full-Text PDF

Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients.

J Clin Sleep Med 2022 Jun 11. Epub 2022 Jun 11.

Stanford University Center for Sleep Sciences and Medicine, Palo Alto, California.

Study Objectives: Evaluate long-term efficacy and safety of sodium oxybate (SXB) in children and adolescents (aged 7-16 years) with narcolepsy with cataplexy.

Methods: A double-blind randomized withdrawal study was conducted. Prior to randomization, SXB-naive participants were titrated to an efficacious and tolerable dose of SXB; participants taking SXB entered on their established dose. Read More

View Article and Full-Text PDF

Idling for Decades: A European Study on Risk Factors Associated with the Delay Before a Narcolepsy Diagnosis.

Nat Sci Sleep 2022 31;14:1031-1047. Epub 2022 May 31.

Center for Sleep Medicine, Sleep Research and Epileptology, Klinik Barmelweid AG, Barmelweid, Aargau, Switzerland.

Purpose: Narcolepsy type-1 (NT1) is a rare chronic neurological sleep disorder with excessive daytime sleepiness (EDS) as usual first and cataplexy as pathognomonic symptom. Shortening the NT1 diagnostic delay is the key to reduce disease burden and related low quality of life. Here we investigated the changes of diagnostic delay over the diagnostic years (1990-2018) and the factors associated with the delay in Europe. Read More

View Article and Full-Text PDF

Somatic genetics analysis of sleep in adult mice.

J Neurosci 2022 Jun 3. Epub 2022 Jun 3.

National Institute of Biological Sciences (NIBS), Beijing 102206, China

Classical forward and reverse mouse genetics require germline mutations and, thus, are unwieldy to study sleep functions of essential genes or redundant pathways. It is also time-consuming to conduct electroencephalogram/electromyogram-based mouse sleep screening owing to labor-intensive surgeries and genetic crosses. Here, we describe a highly accurate SleepV (video) system and adeno-associated virus (AAV)-based adult brain chimeric (ABC)-expression/knockout (KO) platform for somatic genetics analysis of sleep in adult male or female mice. Read More

View Article and Full-Text PDF

Automated classification of cyclic alternating pattern sleep phases in healthy and sleep-disordered subjects using convolutional neural network.

Comput Biol Med 2022 Jul 10;146:105594. Epub 2022 May 10.

Department of Electronics and Computer Engineering, Ngee Ann Polytechnic, Singapore, 599489, Singapore; Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan; Department of Biomedical Engineering, School of Science and Technology, Singapore University of Social Sciences, 599491, Singapore. Electronic address:

Sleep contributes to more than a third of a person's life, making sleep monitoring essential for overall well-being. Cyclic alternating patterns (CAP) are crucial in monitoring sleep quality and associated illnesses such as insomnia, nocturnal frontal lobe epilepsy (NFLE), narcolepsy, etc. However, traditionally medical specialists practice manual division techniques of CAP phases which are sensitive to human weariness and inaccuracies. Read More

View Article and Full-Text PDF

Investigating the Association Between Seven Sleep Traits and Nonalcoholic Fatty Liver Disease: Observational and Mendelian Randomization Study.

Front Genet 2022 17;13:792558. Epub 2022 May 17.

Department of Epidemiology, School of Public Health, Fudan University, Shanghai, China.

Aberrant sleep parameters are associated with the risk of nonalcoholic fatty liver disease (NAFLD). However, existing information is inconsistent among studies and involves reverse causation. Therefore, we aimed to investigate the observational associations and causations between sleep traits and NAFLD. Read More

View Article and Full-Text PDF

Impaired procedural memory in narcolepsy type 1.

Acta Neurol Scand 2022 Jun 2. Epub 2022 Jun 2.

Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Objectives: Sleep enhances the consolidation of memories. Here, we investigated whether sleep-dependent memory consolidation differs between healthy subjects and narcolepsy type 1 (NT1) patients.

Material And Methods: We recruited 18 patients with NT1 and 24 healthy controls. Read More

View Article and Full-Text PDF

Sleep Disturbances in Pediatric Craniopharyngioma: A Systematic Review.

Front Neurol 2022 13;13:876011. Epub 2022 May 13.

Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy.

Craniopharyngiomas are rare brain tumors of the sellar region and are the most common non-neuroepithelial intracerebral neoplasm in children. Despite a low-grade histologic classification, craniopharyngiomas can have a severe clinical course due to hypothalamic involvement. The hypothalamus plays a crucial role in regulating vital functions, and it is a critical component of the sleep-wake regulatory system. Read More

View Article and Full-Text PDF

Gender differences in narcolepsy: What are recent findings telling us?

Sleep 2022 May 30. Epub 2022 May 30.

Department of Neurology, Bern University Hospital (Inselspital) and University Bern, Switzerland.

Three papers currently published in SLEEP using two different mouse models of narcolepsy, including either Hcrt-tTa;TetO diptheria toxin-A (DTA) or Hypocretin knock-out (Hcrt-KO) mice, suggest important gender differences in narcolepsy expression. Specifically, these recent data corroborate previous findings in mice demonstrating that females show more cataplexy events and more total cataplexy expression than males. Moreover, in the neurotoxic DTA mouse model, females show earlier onset of cataplexy expression than males during active Hcrt cell loss. Read More

View Article and Full-Text PDF

Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications.

CNS Drugs 2022 Jun 30;36(6):633-647. Epub 2022 May 30.

Albert Einstein College of Medicine, Bronx, NY, USA.

Background: Lower-sodium oxybate (LXB) is an oxybate medication with the same active moiety as sodium oxybate (SXB) and a unique composition of cations, resulting in 92% less sodium. LXB was shown to improve cataplexy and excessive daytime sleepiness in people with narcolepsy in a placebo-controlled, double-blind, randomized withdrawal study (NCT03030599). Additional analyses of data from this study were conducted to explore the effects of LXB on cataplexy, including the clinical course and feasibility of transition from other anticataplectics to LXB monotherapy. Read More

View Article and Full-Text PDF

Metabolic-Syndrome-Related Comorbidities in Narcolepsy Spectrum Disorders: A Preliminary Cross-Sectional Study in Japan.

Int J Environ Res Public Health 2022 05 22;19(10). Epub 2022 May 22.

Japan Somnology Center, Neuropsychiatric Research Institute, 5-10-10, Yoyogi, Shinjuku-ku, Tokyo 151-0053, Japan.

Narcolepsy types 1 (NT1) and 2 (NT2) and idiopathic hypersomnia (IH) are thought to be a disease continuum known as narcolepsy spectrum disorders (NSDs). This study aimed to assess the prevalence of and factors associated with metabolic-syndrome-related disorders (MRDs) among patients with NSD. Japanese patients with NSD (NT1, = 94; NT2, = 83; and IH, = 57) aged ≥35 years were enrolled in this cross-sectional study. Read More

View Article and Full-Text PDF

Narcolepsy.

J Sleep Res 2022 May 27:e13631. Epub 2022 May 27.

Sleep-Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, Montpellier, France.

This article addresses the clinical presentation, diagnosis, pathophysiology and management of narcolepsy type 1 and 2, with a focus on recent findings. A low level of hypocretin-1/orexin-A in the cerebrospinal fluid is sufficient to diagnose narcolepsy type 1, being a highly specific and sensitive biomarker, and the irreversible loss of hypocretin neurons is responsible for the main symptoms of the disease: sleepiness, cataplexy, sleep-related hallucinations and paralysis, and disrupted nocturnal sleep. The process responsible for the destruction of hypocretin neurons is highly suspected to be autoimmune, or dysimmune. Read More

View Article and Full-Text PDF

Correction to: Narcolepsy: a model interaction between immune system, nervous system, and sleep-wake regulation.

Semin Immunopathol 2022 May 26. Epub 2022 May 26.

Clinical Sleep and Neuroimmunology, Institute of Immunology, University Witten/Herdecke, Witten, Germany.

View Article and Full-Text PDF

Molecular mechanism of the wake-promoting agent TAK-925.

Nat Commun 2022 May 25;13(1):2902. Epub 2022 May 25.

Department of Biophysics, The University of Texas Southwestern Medical Center, 6001 Forest Park Road, Dallas, TX, 75390, USA.

The OX orexin receptor (OXR) is a highly expressed G protein-coupled receptor (GPCR) in the brain that regulates wakefulness and circadian rhythms in humans. Antagonism of OXR is a proven therapeutic strategy for insomnia drugs, and agonism of OXR is a potentially powerful approach for narcolepsy type 1, which is characterized by the death of orexinergic neurons. Until recently, agonism of OXR had been considered 'undruggable. Read More

View Article and Full-Text PDF

Is There a Place for Medicinal Cannabis in Treating Patients with Sleep Disorders? What We Know so Far.

Nat Sci Sleep 2022 18;14:957-968. Epub 2022 May 18.

West Australian Sleep Disorders Research Institute, Department of Pulmonary Physiology & Sleep Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.

The legalization of cannabis for medicinal, and in some countries, recreational, purposes in addition to growth in the cannabis industry has meant that cannabis use and interest in the area has increased rapidly over the past 20 years. Treatment of poor sleep and sleep disorders are two of the most common reasons for the current use of medicinal cannabis. However, evidence for the role of medical cannabis in the treatment of sleep disorders has not been clearly established, thus making it challenging for clinicians to make evidence-based decisions regarding efficacy and safety. Read More

View Article and Full-Text PDF

Modafinil acquires reinforcing effects when combined with citalopram.

Pharmacol Biochem Behav 2022 06 20;217:173407. Epub 2022 May 20.

Laboratorio de Farmacología y Conducta, Instituto de Neurociencias, CUCBA, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico. Electronic address:

Modafinil (MOD) is a wakefulness promoter used to treat sleep disorders such as narcolepsy and obstructive sleep apnea. Its action mechanism consists in inhibiting dopamine (DAT) and norepinephrine (NET) transporters, but it has no affinity for the serotonin transporter (SERT). Modafinil's addictive potential is not yet clear, but one feature that differentiates it from potentially addictive drugs like cocaine revolves around affinity for SERT. Read More

View Article and Full-Text PDF

Effect of Modafinil on functional connectivity in healthy young people using resting-state fMRI data.

Am J Neurodegener Dis 2022 15;11(1):1-9. Epub 2022 Apr 15.

Department of Biostatistics, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences Tehran, Iran.

Background: Examining the differences in the Functional Connectivity (FC) network while using Functional Magnetic Resonance Imaging (fMRI) between two groups can expand the understanding of neural processes and help diagnose and prevent neurological progression disorders. The present study evaluated the Modafinil effect on the FC of brain Regions of Interest (ROI) among healthy young individuals between the Modafinil and placebo groups.

Method: The data used in this study were downloaded from the open fMRI site and analyzed after preprocessing. Read More

View Article and Full-Text PDF